Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study
article
OA: closed
CC0
⤵ 6 in-corpus citations
Abstract
OBJECTIVE: To investigate the safety and efficacy of adjuvant gonadotropin-releasing hormone agonist (GnRH-a) treatment followed by maintenance dienogest (DNG) therapy after uterus-sparing surgery. METHODS: Retrospective cohort study. A total of 190 patients with severe adenomyosis underwent uterus-sparing surgery between January 2010 and June 2020. Of these patients, 90 were analyzed. Forty-six patients (control group) received adjuvant 6-month GnRH-a therapy alone after uterus-sparing surgery, and 44 patients (maintenance group) received postoperative 6-month GnRH-a treatment followed by maintenance DNG therapy (2 mg/day orally). The median follow-up period was 18 months. The study was analyzed using generalized estimating equations. RESULTS: At baseline, the characteristics of patients in each group were comparable. Compared with the control group, the maintenance group had a significant improvement in the visual analog scale score of dysmenorrhea (P < 0.001), hemoglobin level (P = 0.004), and uterine volume (P = 0.004) from baseline to 18 months after uterus-sparing surgery. The symptom recurrence rate was significantly lower in the maintenance group than in the control group (4.6% vs. 37.0%, P < 0.001). CONCLUSIONS: The findings of this study suggest that combinatorial treatment with GnRH-a (adjuvant treatment) and DNG (maintenance therapy) represents a safe and effective short-term therapy after uterus-sparing surgery for adenomyosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (33)
- Adenomyosis and Infertility—Review of Medical and Surgical Approaches via openalex
- A Systematic Review of Adenomyosis: It Is Time to Reassess What We Thought We Knew about the Disease via openalex
- Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy via openalex
- Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial via openalex
- Conservative surgical management for diffuse uterine adenomyosis via openalex
- Diagnosing adenomyosis: an integrated clinical and imaging approach via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Epidemiology of Adenomyosis via openalex
- Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- Oestrogen‐induced angiogenesis promotes adenomyosis by activating the <scp>S</scp>lug‐<scp>VEGF</scp> axis in endometrial epithelial cells via openalex
- Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. via openalex
- Pathology and Pathogenesis of Adenomyosis via openalex
- Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma via openalex
- Prevalence and risk factors of adenomyosis at hysterectomy via openalex
- Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest via openalex
- Relationship between the serum cancer antigen 125 level and the weight of surgically enucleated adenomyosis via openalex
- Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest via openalex
- Severe adenomyosis and CA125 via openalex
- Sonographic classification and reporting system for diagnosing adenomyosis via openalex
- Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis via openalex
- The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis via openalex
- Transvaginal Sonographic Criteria for the Diagnosis of Adenomyosis Based on Histopathologic Correlation via openalex
- Uterine adenomyosis and adenomyoma: the surgical approach via openalex
- W2873462695 via openalex
- W2997726328 via openalex
- W2081898822 via openalex
- W2065386825 via openalex
- W2114428497 via openalex
- W2019524523 via openalex
- W2739010978 via openalex
- W6785042710 via openalex
- W2736858912 via openalex
- W2790094279 via openalex
Cited by (6)
- The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis 2024
- Heavy uterine bleeding in women with endometriosis and adenomyosis treated with dienogest 2024
- Long-term dienogest treatment in endometriosis: Consensus from Taiwanese experts 2024
- Dienogest treatment in women with endometriosis: A retrospective cohort study in Taiwan 2024
- Both adjuvant and maintenance therapies are needed in women with symptomatic adenomyosis after uterus-sparing treatment 2023
- Meta-Analysis on the Therapeutic Effectiveness of Dienogest plus GnRH Agonist in Treating Adenomyosis and Its Related Obstetric Risk Factors 2021
SciLite annotations
chemicals 2
dienogest
dienogest
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-27T00:34:13.482206+00:00
- scilite
- last seen: 2026-05-18T04:25:29.313245+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK